Aurobindo Pharma falls over 20% on receiving USFDA observations

KS Badri Narayanan Chennai | Updated on October 07, 2019 Published on October 07, 2019

File photo


Shares of Aurobindo Pharma crashed over 20 per cent on Monday, following the US drug regulator's adverse observation.

After hitting a year low of ₹450.35, the stock ended the day at ₹451.70, down 20.41 per cent, on the NSE.

The USFDA has issued a note (after inspecting Aurobindo’s Unit-7 between September 19-27, 2019) indicating procedural lapses along with lack of Quality control.

The USFDA observations are as follows: Failure to review any unexplained discrepancy; failure to consider failure of batch or components; Control procedures not established; No written procedures for production and process controls; Equipment and utensils not cleaned at appropriate levels; Procedures applicable to Quality control not thoroughly followed; and written production and process controls not developed in execution of production, process controls.

Published on October 07, 2019
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.